Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Su Wang, PhD, Daisuke Ogiya, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth Wen, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139778

Published: 2020

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, Phillip A Hsieh, Metin Kurtoglu, MD PhD, Yi Zhang, C Andrew Stewart, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1811.

https://doi.org/10.1182/blood-2019-121595

Published: 2019

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Lijie Xing, MD, Yuyin Li, PhD, Liang Lin, PhD, Tengteng Yu, MD PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3096.

https://doi.org/10.1182/blood-2019-127135

Published: 2019

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Yuyin Li, PhD, Liang Lin, PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Tengteng Yu, MD PhD, Gang An, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4381.

https://doi.org/10.1182/blood-2019-130297

Published: 2019

Journal Articles

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip Hsieh, Gang An, MD, Lugui Qiu, MD PhD, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 407.

https://doi.org/10.1182/blood-2018-99-110317

Published: 2018

Journal Articles

An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma

Tengteng Yu, MD, Lijie Xing, MD, Liang Lin, PhD, Jiye Liu, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip Hsieh, James Myette, Bharat Chaganty, Hedy Adari, Hamid Tissire, Ketan Deotale, Zach Shriver, Nikhil Munshi, MD, Yu-Tzu Tai, PhD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 5617.

https://doi.org/10.1182/blood-2018-99-119112

Published: 2018

Journal Articles

Anti-BCMA BiTE ® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Jiye Liu, PhD, Tengteng Yu, MD, Kenneth Wen, BS, Phillip Hsieh, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 592.

https://doi.org/10.1182/blood-2018-99-118425

Published: 2018

Journal Articles

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

Jiye Liu, PhD, Wenrong Zhou, PhD, Lijie Xing, MD, Liang Lin, PhD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2018-99-111962

Published: 2018

Journal Articles

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Yu-Tzu Tai, PhD, John Dulos, PhD, Lars Guelen, Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip A Hsieh, Peter van Zandvoort, Bsc, Guido van de Wiel, Jos van de Crommert, Bsc, Bonny Lejeune, Hamid Namini, Hans Eenennaam, PhD, Andrea van Elsas, PhD, Paul Richardson, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2018-99-117296

Published: 2018

Journal Articles

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Blood (2018) 132 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2018-99-118994

Published: 2018

Journal Articles

A Proliferation Inducing Ligand (APRIL) Directly Impacts Immune Regulatory Subsets to Regulate Suppressive Multiple Myeloma Bone Marrow Microenvironment

Yu-Tzu Tai, PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, BS, Phillip Hsieh, An Gang, MD, Lugui Qiu, MD, Nikhil Munshi, MD, Paul G Richardson, MD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 3066.

https://doi.org/10.1182/blood.V130.Suppl_1.3066.3066

Published: 2017

Journal Articles

CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo

Liang Lin, PhD, Lijie Xing, MD, Chirag M Acharya, MBBS, Kenneth Wen, BS, Jiye Liu, PhD, Phillip Hsieh, Metin Kurtoglu, MD PhD, Jeffrey Holderness, MD, Murat Kalayoglu, MD PhD, Nikhil Munshi, MD, Paul G Richardson, MD, Kenneth C Anderson, MD, Yu-Tzu Tai, PhD

Blood (2017) 130 (Supplement 1): 3067.

https://doi.org/10.1182/blood.V130.Suppl_1.3067.3067

Published: 2017

Journal Articles

A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication

Liang Lin, PhD, Lijie Xing, MD, Chirag M Acharya, MBBS, Kenneth Wen, BS, Phillip Hsieh, John Dulos, PhD, Andrea Van Elsas, PhD, Nikhil Munshi, MD, Paul G Richardson, MD, Kenneth C Anderson, MD, Yu-Tzu Tai, PhD

Blood (2017) 130 (Supplement 1): 499.

https://doi.org/10.1182/blood.V130.Suppl_1.499.499

Published: 2017

Journal Articles

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Blood (2017) 130 (Supplement 1): 1755.

https://doi.org/10.1182/blood.V130.Suppl_1.1755.1755

Published: 2017

Journal Articles

Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications

Jiye Liu, PhD, Wenrong Zhou, PhD, Lijie Xing, MD, Matthew Ho, Kenneth Wen, BS, Tianyu Song, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Yong Cang, PhD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 594.

https://doi.org/10.1182/blood.V130.Suppl_1.594.594

Published: 2017

NARROW

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma

Anti-BCMA BiTE ® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

A Proliferation Inducing Ligand (APRIL) Directly Impacts Immune Regulatory Subsets to Regulate Suppressive Multiple Myeloma Bone Marrow Microenvironment

CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo

A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only